FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105956656> ?p ?o ?g. }

• W2105956656 abstract "Background Indomethacin is a prostaglandin inhibitor used to treat patent ductus arteriosus (PDA) in preterm infants. Although indomethacin produces ductal closure in the majority of cases, it is ineffective in up to 40% of patients. Furthermore, the ductus will re‐open in up to 35% of infants who initially respond to the drug. Prolonging the course of indomethacin has the potential to achieve higher rates of ductal closure. Objectives To determine the effect of a prolonged course of indomethacin (compared to a short course) on the rate of treatment failure without unwanted side‐effects in preterm infants with PDA. Search methods The search included review of personal files, abstracts of conferences, and the following electronic databases: MEDLINE (1966 to December 2006), EMBASE (1974 to December 2006), and Oxford Database of Perinatal Trials, Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2006). No language restrictions were applied. Selection criteria Randomized or quasi‐randomized controlled trials including preterm infants with PDA, diagnosed on clinical and/or echocardiographic examination that evaluated indomethacin treatment by any route given as a long course (four or more doses) vs. a short course (three or fewer doses) were included in the review. Trials needed to report on at least one of the following outcomes: failure of PDA to close, need for re‐treatment, PDA re‐opening, PDA ligation, mortality, duration of assisted ventilation, chronic lung disease (CLD), duration of supplemental oxygen dependence, intraventricular hemorrhage (IVH) (all and severe), diminished urine output, increased serum creatinine, necrotizing enterocolitis (NEC), bleeding diathesis, retinopathy of prematurity (ROP), and duration of hospital stay. Data collection and analysis The three review authors independently abstracted data from each study. Relative risk (RR) and Risk Difference (RD) with 95% confidence intervals (CI) using the fixed effect model for meta‐analysis are reported. When a statistically significant RD was found, the number needed to treat (NNT) or number needed to harm (NNH) was also calculated with 95% CIs. The I squared statistic was used to test for heterogeneity of results among included trials. Main results Five trials met inclusion criteria and included 431 infants. Prolonged indomethacin treatment when compared to the short course did not result in a statistically significant difference in PDA closure, re‐treatment, re‐opening, or ligation rates. The prolonged course was associated with an increased risk of NEC [typical RR 1.87 (95% CI 1.07, 3.27); typical RD 0.08 (95% CI 0.01, 0.15); NNH 13 (7, 100)] and a decreased incidence of renal function impairment, as evidenced by a lower proportion of infants having diminished urine output [typical RR 0.27 (95% CI 0.13, 0.6); typical RD ‐0.19 (95% CI ‐0.28, ‐0.09); NNT 5 (4, 11)] and increased serum creatinine level [typical RR 0.51 (95% CI 0.33, 0.77); typical RD ‐0.14 (95% CI ‐0.23, ‐0.06); NNT 7 (4, 16)]. Authors' conclusions Implications for practice Prolonged indomethacin course does not appear to have a significant effect on improving important outcomes, such as PDA treatment failure, CLD, IVH, or mortality. The reduction of transient renal impairment does not outweigh the increased risk of NEC associated with the prolonged course. Based on these results, a prolonged course of indomethacin cannot be recommended for the routine treatment of PDA in preterm infants. Implications for research There is a paucity of data on optimal dosing and duration of indomethacin therapy for the treatment of PDA, in particular for extremely low birth weight infants (ELBW) premature infants. It is likely that a single standard indomethacin regime is not the ideal for every premature infant. Therefore, individual patient response should be considered and evaluated, in particular in ELBW infants. Future randomized clinical trials should include this high risk population and investigate the effect of tailoring dose and duration of therapy to individual response in terms of echocardiographic findings and/or prostaglandin levels, focusing on clinically significant outcomes, including long‐term neurodevelopmental outcomes. In addition, factors that may influence treatment effect, such as birth weight, gestational age, age at the time of randomization, total fluid intake, feeding practice, and severity of PDA, need to be taken into account when designing such studies." @default.
• W2105956656 created "2016-06-24" @default.
• W2105956656 creator A5017591364 @default.
• W2105956656 creator A5041821959 @default.
• W2105956656 creator A5077340957 @default.
• W2105956656 date "2007-04-18" @default.
• W2105956656 modified "2023-10-16" @default.
• W2105956656 title "Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants" @default.
• W2105956656 cites W1519084990 @default.
• W2105956656 cites W163151552 @default.
• W2105956656 cites W1971778935 @default.
• W2105956656 cites W1977819117 @default.
• W2105956656 cites W1980238877 @default.
• W2105956656 cites W1982882214 @default.
• W2105956656 cites W1990042927 @default.
• W2105956656 cites W1995679247 @default.
• W2105956656 cites W2005646040 @default.
• W2105956656 cites W2013186332 @default.
• W2105956656 cites W2018210725 @default.
• W2105956656 cites W2018560295 @default.
• W2105956656 cites W2019549525 @default.
• W2105956656 cites W2037271954 @default.
• W2105956656 cites W2040478286 @default.
• W2105956656 cites W2046224781 @default.
• W2105956656 cites W2050332672 @default.
• W2105956656 cites W2075070761 @default.
• W2105956656 cites W2077237914 @default.
• W2105956656 cites W2085890271 @default.
• W2105956656 cites W2090093894 @default.
• W2105956656 cites W2105956656 @default.
• W2105956656 cites W2122958974 @default.
• W2105956656 cites W2127772690 @default.
• W2105956656 cites W2316480452 @default.
• W2105956656 doi "https://doi.org/10.1002/14651858.cd003480.pub3" @default.
• W2105956656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17443527" @default.
• W2105956656 hasPublicationYear "2007" @default.
• W2105956656 type Work @default.
• W2105956656 sameAs 2105956656 @default.
• W2105956656 citedByCount "62" @default.
• W2105956656 countsByYear W21059566562012 @default.
• W2105956656 countsByYear W21059566562013 @default.
• W2105956656 countsByYear W21059566562014 @default.
• W2105956656 countsByYear W21059566562015 @default.
• W2105956656 countsByYear W21059566562016 @default.
• W2105956656 countsByYear W21059566562017 @default.
• W2105956656 countsByYear W21059566562018 @default.
• W2105956656 countsByYear W21059566562019 @default.
• W2105956656 countsByYear W21059566562021 @default.
• W2105956656 countsByYear W21059566562022 @default.
• W2105956656 countsByYear W21059566562023 @default.
• W2105956656 crossrefType "journal-article" @default.
• W2105956656 hasAuthorship W2105956656A5017591364 @default.
• W2105956656 hasAuthorship W2105956656A5041821959 @default.
• W2105956656 hasAuthorship W2105956656A5077340957 @default.
• W2105956656 hasBestOaLocation W21059566562 @default.
• W2105956656 hasConcept C126322002 @default.
• W2105956656 hasConcept C168563851 @default.
• W2105956656 hasConcept C187212893 @default.
• W2105956656 hasConcept C2776478404 @default.
• W2105956656 hasConcept C2778376644 @default.
• W2105956656 hasConcept C2778721537 @default.
• W2105956656 hasConcept C2779234561 @default.
• W2105956656 hasConcept C2779252433 @default.
• W2105956656 hasConcept C2779303187 @default.
• W2105956656 hasConcept C2779918416 @default.
• W2105956656 hasConcept C2781236024 @default.
• W2105956656 hasConcept C42219234 @default.
• W2105956656 hasConcept C54355233 @default.
• W2105956656 hasConcept C71924100 @default.
• W2105956656 hasConcept C86803240 @default.
• W2105956656 hasConceptScore W2105956656C126322002 @default.
• W2105956656 hasConceptScore W2105956656C168563851 @default.
• W2105956656 hasConceptScore W2105956656C187212893 @default.
• W2105956656 hasConceptScore W2105956656C2776478404 @default.
• W2105956656 hasConceptScore W2105956656C2778376644 @default.
• W2105956656 hasConceptScore W2105956656C2778721537 @default.
• W2105956656 hasConceptScore W2105956656C2779234561 @default.
• W2105956656 hasConceptScore W2105956656C2779252433 @default.
• W2105956656 hasConceptScore W2105956656C2779303187 @default.
• W2105956656 hasConceptScore W2105956656C2779918416 @default.
• W2105956656 hasConceptScore W2105956656C2781236024 @default.
• W2105956656 hasConceptScore W2105956656C42219234 @default.
• W2105956656 hasConceptScore W2105956656C54355233 @default.
• W2105956656 hasConceptScore W2105956656C71924100 @default.
• W2105956656 hasConceptScore W2105956656C86803240 @default.
• W2105956656 hasIssue "1" @default.
• W2105956656 hasLocation W21059566561 @default.
• W2105956656 hasLocation W21059566562 @default.
• W2105956656 hasLocation W21059566563 @default.
• W2105956656 hasOpenAccess W2105956656 @default.
• W2105956656 hasPrimaryLocation W21059566561 @default.
• W2105956656 hasRelatedWork W2012070424 @default.
• W2105956656 hasRelatedWork W2349639015 @default.
• W2105956656 hasRelatedWork W2499499609 @default.
• W2105956656 hasRelatedWork W2603361761 @default.
• W2105956656 hasRelatedWork W2891011641 @default.
• W2105956656 hasRelatedWork W2897309798 @default.
• W2105956656 hasRelatedWork W3031262609 @default.
• W2105956656 hasRelatedWork W415308517 @default.
• W2105956656 hasRelatedWork W4253061985 @default.

• next